Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$3.08
0.010.33%
At close: Dec 15, 4:00 PM EST
$3.19
0.113.57%
After Hours: 8:55 AM EST
Comments
Loading...
Oramed Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:ORMP | Benzinga
Oramed Pharmaceuticals Inc has a consensus price target of $2 based on the ratings of 2 analysts. The high is $2 issued by Canaccord Genuity on May 17, 2023. The low is $2 issued by Canaccord Genuity on May 17, 2023. The 1 most-recent analyst ratings were released by Canaccord Genuity on May 17, 2023, respectively. With an average price target of $2 between Canaccord Genuity, there's an implied -37.30% downside for Oramed Pharmaceuticals Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Canaccord Genuity
1calculated from analyst ratings
Analyst Ratings for Oramed Pharmaceuticals
FAQ
What is the target price for Oramed Pharmaceuticals (ORMP) stock?
The latest price target for Oramed Pharmaceuticals (NASDAQ:ORMP) was reported by HC Wainwright & Co. on September 9, 2024. The analyst firm set a price target for $0.00 expecting ORMP to fall to within 12 months (a possible -100.00% downside). 0 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Oramed Pharmaceuticals (ORMP)?
The latest analyst rating for Oramed Pharmaceuticals (NASDAQ:ORMP) was provided by HC Wainwright & Co., and Oramed Pharmaceuticals reiterated their neutral rating.
When was the last upgrade for Oramed Pharmaceuticals (ORMP)?
There is no last upgrade for Oramed Pharmaceuticals
When was the last downgrade for Oramed Pharmaceuticals (ORMP)?
The last downgrade for Oramed Pharmaceuticals Inc happened on January 17, 2023 when HC Wainwright & Co. changed their price target from N/A to N/A for Oramed Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Oramed Pharmaceuticals (ORMP)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Oramed Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Oramed Pharmaceuticals was filed on September 9, 2024 so you should expect the next rating to be made available sometime around September 9, 2025.
Is the Analyst Rating Oramed Pharmaceuticals (ORMP) correct?
While ratings are subjective and will change, the latest Oramed Pharmaceuticals (ORMP) rating was a reiterated with a price target of $0.00 to $0.00. The current price Oramed Pharmaceuticals (ORMP) is trading at is $3.19, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
